[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360206-105":59,"doc-detail-360206-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","adenosine-signaling-in-primary-and-metastatic-brain-tumors-immune-suppression-tumor-progression-and-therapeutic-opportunities","Adenosine Signaling in Primary and Metastatic Brain Tumors - Immune Suppression, Tumor Progression, and Therapeutic Opportunities","","Brain tumors, whether primary or metastatic, remain a major driver of cancer-related mortality, shaped by a profoundly immunosuppressive tumor microenvironment (TME). Purinergic signaling, especially the adenosine (ADO) axis, regulates tumor progression by converting extracellular ATP to ADO through CD39 and CD73 and sustaining adenosine P1 receptor activation. This review compares receptor-specific roles of A1, A2A, A2B, and A3 in neuroinflammation, immune evasion, and therapeutic resistance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/adenosine-signaling-in-primary-and-metastatic-brain-tumors-immune-suppression-tumor-progression-and-therapeutic-opportunities/360206/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/adenosine-signaling-in-primary-and-metastatic-brain-tumors-immune-suppression-tumor-progression-and-therapeutic-opportunities/360206.png","ImageObject",300,407,{"name":92,"@type":93},"Cipher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does extracellular ATP become adenosine in the tumor microenvironment?","Question",{"text":112,"@type":113},"Extracellular ATP (eATP) is sequentially converted into adenosine (ADO) by ectonucleotidases CD39 and CD73, which sustains activation of adenosine P1 receptors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What roles do adenosine receptors play in brain tumors?",{"text":117,"@type":113},"The review highlights receptor-specific effects of A1, A2A, A2B, and A3 on neuroinflammation, immune evasion, and therapeutic resistance, with signaling patterns that shift as ADO accumulates.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is pathological adenosine signaling linked to immune evasion and therapeutic resistance?",{"text":121,"@type":113},"Sustained ADO accumulation disrupts homeostatic balance: low-affinity receptors become engaged, prolonged A2A activation can switch to immunosuppressive signaling, and this contributes to T-cell dysfunction and tumor-supportive processes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360206,1790175070,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687208528416,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Molecular Neurobiology (2026) 63:644  \n[https://doi.org/10.1007/s12035-026-05930-9](https://doi.org/10.1007/s12035-026-05930-9)  \nAdenosine Signaling in Primary and Metastatic Brain Tumors: Immune Suppression, Tumor Progression, and Therapeutic Opportunities  \nTiago de Oliveira Lima1,2 · Adinei Abadio Soares3 · Bernardo Ribeiro Böhm3 · Bruna Marciano Teixeira4 · Luiz Cláudio Teixeira da Costa5 · Kailane Paula Pretto6 · João Victor Garcia de Souza7 ·  \nMarcelo Lemos Vieira da Cunha8,9,10 · Claudiana Lameu11 · Detlev Boison12,13,14 ·  \nDébora Tavares de Resende eSilva7  \nReceived: 6 February 2026 / Accepted: 13 May 2026 © The Author(s) 2026  \nAbstract  \nBrain tumors, whether primary or metastatic, remain a significant cause of cancer-related mortality and are characterized by a profoundly immunosuppressive tumor microenvironment (TME). Among the signaling pathways that shape this environment, purinergic signaling—particularly the adenosine (ADO) axis—has emerged as a central regulator of tumor progression. In the TME, extracellular ATP (eATP) is sequentially converted into ADO by the ectonucleotidases CD39 and CD73, leading to sustained activation of adenosine P1 receptors. This review examines the receptor-specific roles of A1, A2A, A2B, and A3 receptors in modulating neuroinflammation, immune evasion, and therapeutic resistance across distinct brain tumor entities. At low extracellular ADO concentrations, high-affinity A1 and A2A receptors dominate signaling; A1 receptor (A1R) activation predominantly exerts neuroprotective effects by limiting glutamatergic excitotoxicity and preserving blood–brain barrier (BBB) integrity. However, under pathological conditions characterized by sustained ADO accumulation, this homeostatic balance is disrupted. Elevated ADO levels progressively engage low-affinity A2B and A3 receptors, while prolonged A2A receptor activation shifts from regulatory to immunosuppressive signaling, collectively driving T-cell dysfunction, angiogenesis, glioblastoma stem-like cell maintenance, and metastatic competence. Taken together, these findings highlight that pathological ADO receptor engagement in brain tumors is governed by extracellular ADO availability and receptor affinity, supporting a pharmacological framework in which selective inhibition of A2B and A3 receptors, combined with context-dependent modulation of A2A and preservation of A1R-mediated neuroprotective signaling, represents a rational strategy to limit tumor progression while minimizing adverse neurological effects.  \nKeywords Adenosine · Cancer · Purinergic signaling  \nIntroduction  \nMillions of new cancer cases are predicted annually worldwide [1–3]. These malignant tumors remain among the leading causes of disease-related deaths [3], with brain tumors associated with particularly high mortality rates. As brain tumors can be either primary or secondary, their origins vary, and consequently, the pathophysiology is specific to each tumor type. Notwithstanding their divergent characteristics, the evidence suggests that certain properties are likely  \nTiago de Oliveira Lima and Adinei Abadio Soares contributed equally to this work.  \nExtended author information available on the last page of the article  \nto be shared among these tumor types, given the specialized brain microenvironment. Moreover, the effective targeting of brain tumors is often challenging, and novel strategies to address brain tumor-associated mechanisms involve modulation of signaling within the TME. It is well established that cancerous cells hijack a wide range of physiological processes in the TME, exploiting signals from immune and stromal cells to support their metabolism, with purinergic  \nsignaling playing a key role in brain tumor progression. Purinergic signaling is mediated through receptors, which are classified into the P1 receptors, A1, A2A, A2B, and A3 activated by adenosine (ADO), and P2 receptors, activated by eATP and other nucleotides such as ADP and UTP, P2X","cbCaip1CDDOgSDsU","https://ap.wps.com/l/cbCaip1CDDOgSDsU","pdf",1339116,17,"English","# Abstract\n# Introduction\n## Purinergic signaling in brain tumor progression\n## P1 and P2 receptors and their roles in the TME\n## ATP-to-ADO degradation via CD39 and CD73\n## Rationale and aims of the review","[{\"question\":\"How does extracellular ATP become adenosine in the tumor microenvironment?\",\"answer\":\"Extracellular ATP (eATP) is sequentially converted into adenosine (ADO) by ectonucleotidases CD39 and CD73, which sustains activation of adenosine P1 receptors.\"},{\"question\":\"What roles do adenosine receptors play in brain tumors?\",\"answer\":\"The review highlights receptor-specific effects of A1, A2A, A2B, and A3 on neuroinflammation, immune evasion, and therapeutic resistance, with signaling patterns that shift as ADO accumulates.\"},{\"question\":\"Why is pathological adenosine signaling linked to immune evasion and therapeutic resistance?\",\"answer\":\"Sustained ADO accumulation disrupts homeostatic balance: low-affinity receptors become engaged, prolonged A2A activation can switch to immunosuppressive signaling, and this contributes to T-cell dysfunction and tumor-supportive processes.\"}]","Adenosine Signaling in Primary and Metastatic Brain Tumors - Immune Suppression, Tumor Progression, and Therapeutic Opportunities | PDF",1790139071,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1803a63816b720bc5a03e6fdd169fbaa.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/732cdf96b1e14d07b8f4cb9d42f86a2b.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/461d31652bc14384887acc7f3b41eb58.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a46cd0743f26612d2c0d53a6340c4a9e.webp",980,1301]